Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.29)
# 2,798
Out of 5,111 analysts
52
Total ratings
30.61%
Success rate
4.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Initiates: Overweight | $18 | $6.58 | +173.56% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.42 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.64 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $85.67 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $49.21 | +103.21% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.36 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.25 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.24 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $16.90 | - | 1 | Dec 9, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $4.91 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.27 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $41.92 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.63 | +206.75% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.06 | +531.07% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $22.64 | -64.66% | 1 | Mar 20, 2023 |
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $6.58
Upside: +173.56%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.64
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $85.67
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $49.21
Upside: +103.21%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.36
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.25
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.24
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.90
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.91
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.27
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $41.92
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.63
Upside: +206.75%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.06
Upside: +531.07%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $22.64
Upside: -64.66%